Target mRNA inhibition by oligonucleotide drugs in man

Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial

(2012) Maartje E. Visser et al.   EUROPEAN HEART JOURNAL

Obatoclax mesylate: pharmacology and potential for therapy of hematological neoplasms

(2012) Jamal Joudeh et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Cancer drug's survivin suppression called into question

(2012) David Holmes   NATURE MEDICINE

Outlook for the next 5 years in drug innovation

(2012) Roy Berggren et al.   NATURE REVIEWS DRUG DISCOVERY

Survivin in Solid Tumors: Rationale for Development of Inhibitors

(2012) David N. Church et al.   Current Oncology Reports

Molecular Imaging and Pharmacokinetic Analysis of Carbon-11 Labeled Antisense Oligonucleotide LY2181308 in Cancer Patients

(2012) Azeem Saleem et al.   Theranostics

Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor

(2011) N. A. Molfino et al.   CLINICAL AND EXPERIMENTAL ALLERGY

TPI ASM8 reduces eosinophil progenitors in sputum after allergen challenge

(2011) H. Imaoka et al.   CLINICAL AND EXPERIMENTAL ALLERGY

Therapeutic Oligonucleotides: The Road Not Taken

(2011) C. A. Stein et al.   CLINICAL CANCER RESEARCH

A Phase 1 Dose Escalation, Pharmacokinetic, and Pharmacodynamic Evaluation of eIF-4E Antisense Oligonucleotide LY2275796 in Patients with Advanced Cancer

(2011) D. S. Hong et al.   CLINICAL CANCER RESEARCH

Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c

(2011) F. Saad et al.   CLINICAL CANCER RESEARCH

Therapeutic potential of antisense oligonucleotides for the management of dyslipidemia

(2011) Rosanne M Crooke et al.   Clinical Lipidology

Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia

(2011) Fatima Akdim et al.   EUROPEAN HEART JOURNAL

Cellular delivery of siRNA and antisense oligonucleotides via receptor-mediated endocytosis

(2011) Xin Ming   Expert Opinion on Drug Delivery

Pharmacokinetic evaluation of oblimersen sodium for the treatment of chronic lymphocytic leukemia

(2011) Pooja P Advani et al.   Expert Opinion on Drug Metabolism & Toxicology

Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study

(2011) Sebahattin Cirak et al.   LANCET

The long march of antisense

(2011) Dan Jones   NATURE REVIEWS DRUG DISCOVERY

How were new medicines discovered?

(2011) David C. Swinney et al.   NATURE REVIEWS DRUG DISCOVERY

Targeting RNA to treat neuromuscular disease

(2011) Francesco Muntoni et al.   NATURE REVIEWS DRUG DISCOVERY

Systemic Administration of PRO051 in Duchenne's Muscular Dystrophy

(2011) Nathalie M. Goemans et al.   NEW ENGLAND JOURNAL OF MEDICINE

RNA Interference Therapy in Lung Transplant Patients Infected with Respiratory Syncytial Virus

(2010) Martin R. Zamora et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform

(2010) C. Frank Bennett et al.   Annual Review of Pharmacology and Toxicology

A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer

(2010) Srikala S. Sridhar et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Targeting the Cytoprotective Chaperone, Clusterin, for Treatment of Advanced Cancer

(2010) A. Zoubeidi et al.   CLINICAL CANCER RESEARCH

Tumor Survivin Is Downregulated by the Antisense Oligonucleotide LY2181308: A Proof-of-Concept, First-in-Human Dose Study

(2010) D. C. Talbot et al.   CLINICAL CANCER RESEARCH

Apolipoprotein B synthesis inhibition: results from clinical trials

(2010) Maartje E Visser et al.   CURRENT OPINION IN LIPIDOLOGY

Efficacy and Safety of Mipomersen, an Antisense Inhibitor of Apolipoprotein B, in Hypercholesterolemic Subjects Receiving Stable Statin Therapy

(2010) Fatima Akdim et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

(2010) Frederick J Raal et al.   LANCET

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

(2010) Mark E. Davis et al.   NATURE

A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus

(2010) J. DeVincenzo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Phase II Trial of OGX-011 in Combination with Docetaxel in Metastatic Breast Cancer

(2009) S. Chia et al.   CLINICAL CANCER RESEARCH

Treatment of malignant gliomas with TGF-β2 antisense oligonucleotides

(2009) Peter Hau et al.   Expert Review of Anticancer Therapy

Antisense Therapy against CCR3 and the Common Beta Chain Attenuates Allergen-induced Eosinophilic Responses

(2008) Gail M. Gauvreau et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV)

(2008) J DEVINCENZO et al.   ANTIVIRAL RESEARCH

A Phase I Study of OGX-011, a 2'-Methoxyethyl Phosphorothioate Antisense to Clusterin, in Combination with Docetaxel in Patients with Advanced Cancer

(2008) K. N. Chi et al.   CLINICAL CANCER RESEARCH

Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase, in Combination with High-Dose Cytarabine in Patients with Acute Myeloid Leukemia

(2008) R. B. Klisovic et al.   CLINICAL CANCER RESEARCH

Antisense inhibition of ICAM-1 expression as therapy provides insight into basic inflammatory pathways through early experiences in IBD

(2008) Jessica R Philpott et al.   EXPERT OPINION ON BIOLOGICAL THERAPY